Danone’s Oikos Greek yogurt line posted double-digit volume growth in the fourth quarter of 2025, driven by rising adoption of GLP-1 weight-loss medications. According to internal company data, high-protein SKUs grew 14% year-over-year, outpacing total Greek yogurt category gains of 5%. This surge coincides with KFF estimates showing 12% of U.S. adults on GLP-1 therapies as of November 2025. Danone credits targeted marketing to health-conscious consumers and reformulation initiatives that boosted protein content by an average of 25% per serving. Management noted that pricing power on these SKUs is strong, with a premium of up to 10% over standard yogurt varieties, supporting margin expansion in Danone’s Essential Dairy & Plant-Based segment.

In response to updated guidance from certain food safety authorities, Danone has initiated a voluntary recall of a limited number of infant formula batches produced at its Ireland facility. The recall affects approximately 12,000 cartons distributed across three European markets, representing less than 0.2% of Danone’s total Specialized Nutrition production. Routine and additional targeted analyses confirmed that products remain compliant with all applicable safety regulations. Danone has established a dedicated careline to support parents and healthcare professionals, and expects to complete market withdrawals within two weeks. The company reiterated its commitment to food safety and quality assurance protocols, noting no related consumer complaints to date.